Comparative Effectiveness of Atezolizumab, Nivolumab and Pembrolizumab in Second‐Line Treatment of Advanced Non–Small Cell Lung Cancer
The study suggests no evidence of significant differences between the three IO drugs atezolizumab, nivolumab and pembrolizumab when used in second-line aNSCLC. However, wide CIs and moderate sample sizes limit definitive conclusions. These results highlight the need for larger studies to confirm potential equivalence or detect meaningful differences.
Authors
- Simon Boge Brant (ORCID: https://orcid.org/0000-0003-2685-6010)
- Arnoldo Frigessi (ORCID: https://orcid.org/0000-0001-7103-7589)
- Euloge Clovis Kenne Pagui (ORCID: https://orcid.org/0000-0002-8998-9251)
- Christian Jonasson (ORCID: https://orcid.org/0000-0002-7694-6025)
- Åslaug Helland (ORCID: https://orcid.org/0000-0002-5520-0275)
- Kristian Svendsen (ORCID: https://orcid.org/0000-0003-3481-3539)
- Steinar Thoresen
Institutions
- Oslo University Hospital (NO)
- University of Oslo (NO)
- Nordic Semiconductor (Norway) (NO)
Publication Details
- Journal
- Pharmacoepidemiology and Drug Safety
- Published
- 2025-06-24
- DOI
- https://doi.org/10.1002/pds.70181
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Norges Forskningsråd